Utah’s business landscape is rich with professionals who have le...Read More
Social Media and Employers: Friends or Enemies?
The Case for HSAs
Time to Show Up
Make a Move
In the Lab
Rent to Own
Back from the Dead
A Breath of Fresh Air
Travel & Tourism
Draper — Nutranomics, Inc. has entered into a non-binding letter of intent with Genesar Nutraceuticals, LLC, with the intent of completing a licensing agreement to market and distribute GenEpic, a Genesar-developed product that is currently undergoing FDA approved human clinical studies.
"GenEpic is an exciting and very promising natural treatment for prostate cancer that does not consist of chemotherapy or radiation, but rather focuses on adenosine-triphosphate (ATP) inhibition in cells," said Nutranomics' CEO Tracy K. Gibbs. "For the past few weeks, we have been discussing the potential acquisition of the exclusive distribution rights to GenEpic and we are pleased that Genesar now wants to move forward to put together a formal licensing agreement."
GenEpic is a natural therapeutic formula containing 70 vitamins and minerals, 32 herbs, and 16 enzymes and phytonutrients, which are intended to help restore essential nutrients lost due to stress, aging, and disease. GenEpic is currently the subject of an FDA approved human clinical study on prostate cancer treatment and recovery that is expected to be completed within the next 30 days.
The potential completion of a GenEpic distribution license is subject to the parties entering into a definitive agreement.